JP

Jithendra Palakkal

Active Director Director DIN 11368267
DIN 11368267 First appointment Nov 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Jithendra Palakkal

Data last updated:

Jithendra Palakkal is a Director at Phorvia Pharmaceuticals Private Limited (since 2025). The company operates in Pharma.

DIN 11368267
Primary Designation Director
Industry Pharma
First Appointment 05 Nov 2025

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director05 Nov 20252025Active

Directorship timeline

Open interactive timeline →
Phorvia Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Jithendra Palakkal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jithendra Palakkal

Jithendra Palakkal currently holds 1 directorship: Phorvia Pharmaceuticals Private Limited (Director, since 05 Nov 2025).

Jithendra Palakkal was first appointed on 05 Nov 2025 as Director at Phorvia Pharmaceuticals Private Limited.

The current boards of Jithendra Palakkal's companies include Abdul Azeez Kavunga Parambil (Phorvia Pharmaceuticals Private Limited), Pokattu Janardhanan Mukesh (Phorvia Pharmaceuticals Private Limited), Rajeev (Phorvia Pharmaceuticals Private Limited), Saran Karayi Raghavan (Phorvia Pharmaceuticals Private Limited), Sudheer Mohamed Sultan (Phorvia Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available